RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE

Larimar Therapeutics Equity 2024

Larimar Therapeutics Equity

81.72 M USD

Larimar Therapeutics Dividend yield

Ticker

LRMR

ISIN

US5171251003

WKN

A2P5PP

In 2024, Larimar Therapeutics's equity was 81.72 M USD, a -26.31% increase from the 110.9 M USD equity in the previous year.

Larimar Therapeutics Aktienanalyse

What does Larimar Therapeutics do?

Larimar Therapeutics Inc is a US biotechnology company focused on developing therapies for rare genetic diseases. It was founded in 2018 and is based in Philadelphia, Pennsylvania. The company's mission is to accelerate the development of therapies for patients with rare genetic diseases through collaboration with academic researchers, patient organizations, and industry partners. They are active in various therapeutic areas, including neurological diseases, genetic metabolic disorders, and rare inherited diseases, with a diverse portfolio of drug candidates in different stages of clinical development. Their main focus is on developing therapies for Friedreich's ataxia, a rare neurological disease, and other neurologic disorders. They are also working on therapies for rare genetic metabolic disorders such as PKU and HFI. Larimar Therapeutics aims to improve the quality of life for patients with rare inherited diseases and adopts an innovative and patient-centered approach to their drug development. Collaborations and partnerships are integral to their strategy in order to make faster progress in the treatment of these often severe diseases. Larimar Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Larimar Therapeutics's Equity

Larimar Therapeutics's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Larimar Therapeutics's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Larimar Therapeutics's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Larimar Therapeutics's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Larimar Therapeutics’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Larimar Therapeutics Stock

What is the equity of Larimar Therapeutics this year?

Larimar Therapeutics has equity of 81.72 M USD this year.

What was the equity of Larimar Therapeutics compared to the previous year?

The equity of Larimar Therapeutics has increased/decreased by -26.31% decreased compared to the previous year.

What impact does a high equity have on investors of Larimar Therapeutics?

A high equity is advantageous for investors of Larimar Therapeutics as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Larimar Therapeutics?

A low equity can be a risk for investors of Larimar Therapeutics, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Larimar Therapeutics affect the company?

An increase in equity of Larimar Therapeutics can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Larimar Therapeutics affect the company?

A reduction in equity of Larimar Therapeutics can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Larimar Therapeutics?

Some factors that can affect the equity of Larimar Therapeutics include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Larimar Therapeutics so important for investors?

The equity of Larimar Therapeutics is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Larimar Therapeutics take to change the equity?

To change equity, Larimar Therapeutics can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Larimar Therapeutics pay?

Over the past 12 months, Larimar Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Larimar Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Larimar Therapeutics?

The current dividend yield of Larimar Therapeutics is .

When does Larimar Therapeutics pay dividends?

Larimar Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Larimar Therapeutics?

Larimar Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Larimar Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Larimar Therapeutics located?

Larimar Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Larimar Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Larimar Therapeutics from 5/23/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 5/23/2024.

When did Larimar Therapeutics pay the last dividend?

The last dividend was paid out on 5/23/2024.

What was the dividend of Larimar Therapeutics in the year 2023?

In the year 2023, Larimar Therapeutics distributed 0 USD as dividends.

In which currency does Larimar Therapeutics pay out the dividend?

The dividends of Larimar Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Larimar Therapeutics

Our stock analysis for Larimar Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Larimar Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.